Skip to main content
Top
Published in: Intensive Care Medicine 5/2008

01-05-2008 | Brief Report

Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis

Authors: Jimmy F. P. Berbée, Caroline C. van der Hoogt, Carla J. C. de Haas, Kok P. M. van Kessel, Geesje M. Dallinga-Thie, Johannes A. Romijn, Louis M. Havekes, Henk J. van Leeuwen, Patrick C. N. Rensen

Published in: Intensive Care Medicine | Issue 5/2008

Login to get access

Abstract

Objective

We recently reported that apolipoprotein CI (apoCI) protects against the development of murine bacterial sepsis. We now examined the time course of plasma apoCI levels in survivors and non-survivors of severe sepsis.

Design

Prospective study in patients meeting predefined criteria for severe sepsis.

Setting

University hospital intensive care unit.

Patients and participants

Seventeen patients with severe sepsis.

Interventions

In each patient, serial blood samples for determination of total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apoCI, apoAI, apoB, and apoCIII protein as well as clinical outcome data were collected over 30 days.

Measurements and results

Upon hospitalization, apoCI levels were approximately 5 times lower than normal values in septic patients, i.e. median 1.34 [interquartile range (IQR) 0.82–2.16] mg/dl. ApoCI gradually increased to median values of 5.51 (IQR 3.64–6.97) mg/dl on day 28. At day 0, apoCI levels tended to be lower in non-survivors than in survivors. Remarkably, apoCI levels remained low in non-survivors, whereas apoCI levels gradually increased to normal levels in survivors. This difference was significant and remained so after adjustment for lipoprotein core lipids. No such effect between survivors and non-survivors could be detected for lipoprotein lipids or for apoAI, apoB, and apoCIII after lipid adjustment.

Conclusions

Plasma apoCI levels are markedly decreased in patients with severe sepsis. ApoCI levels were higher in survivors, even after adjustment for lipid levels, and recovered progressively to normal levels. In contrast, apoCI levels remained low in non-survivors. Therefore, a high plasma apoCI level predicts survival in patients with severe sepsis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G (2001) ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 42:281–290PubMed Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G (2001) ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 42:281–290PubMed
2.
go back to reference Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, Barie PS, Rubin AL (1996) Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med 24:584–589PubMedCrossRef Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, Barie PS, Rubin AL (1996) Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med 24:584–589PubMedCrossRef
3.
go back to reference Van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP (2003) Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 31:1359–1366PubMedCrossRef Van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP (2003) Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 31:1359–1366PubMedCrossRef
4.
go back to reference Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96:2758–2767PubMedCrossRef Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96:2758–2767PubMedCrossRef
5.
go back to reference Wu A, Hinds CJ, Thiemermann C (2004) High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 21:210–221PubMedCrossRef Wu A, Hinds CJ, Thiemermann C (2004) High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 21:210–221PubMedCrossRef
6.
go back to reference Berbee JF, Havekes LM, Rensen PC (2005) Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 11:97–103PubMed Berbee JF, Havekes LM, Rensen PC (2005) Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 11:97–103PubMed
7.
go back to reference Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC (2005) High-density lipoprotein function: recent advances. J Am Coll Cardiol 46:1792–1798PubMedCrossRef Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC (2005) High-density lipoprotein function: recent advances. J Am Coll Cardiol 46:1792–1798PubMedCrossRef
8.
go back to reference Berbee JF, van der Hoogt CC, Kleemann R, Schippers EF, Kitchens RL, Van Dissel JT, Bakker-Woudenberg IA, Havekes LM, Rensen PC (2006) Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. FASEB J 20:2162–2164PubMedCrossRef Berbee JF, van der Hoogt CC, Kleemann R, Schippers EF, Kitchens RL, Van Dissel JT, Bakker-Woudenberg IA, Havekes LM, Rensen PC (2006) Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. FASEB J 20:2162–2164PubMedCrossRef
9.
go back to reference Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829PubMedCrossRef Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829PubMedCrossRef
10.
go back to reference Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23:1638–1652PubMedCrossRef Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23:1638–1652PubMedCrossRef
11.
go back to reference Berbee JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC (2005) Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 46:297–306PubMedCrossRef Berbee JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC (2005) Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 46:297–306PubMedCrossRef
12.
go back to reference Schaap FG, Nierman MC, Berbee JF, Hattori H, Talmud PJ, Vaessen SF, Rensen PC, Chamuleau RA, Kuivenhoven JA, Groen AK (2006) Evidence for a complex relationship between apoAV and apoCIII in patients with severe hypertriglyceridemia. J Lipid Res 47:2333–2339PubMedCrossRef Schaap FG, Nierman MC, Berbee JF, Hattori H, Talmud PJ, Vaessen SF, Rensen PC, Chamuleau RA, Kuivenhoven JA, Groen AK (2006) Evidence for a complex relationship between apoAV and apoCIII in patients with severe hypertriglyceridemia. J Lipid Res 47:2333–2339PubMedCrossRef
13.
go back to reference Cohn JS, Tremblay M, Boulet L, Jacques H, Davignon J, Roy M, Bernier L (2003) Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. Atherosclerosis 169:63–70PubMedCrossRef Cohn JS, Tremblay M, Boulet L, Jacques H, Davignon J, Roy M, Bernier L (2003) Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. Atherosclerosis 169:63–70PubMedCrossRef
14.
go back to reference Shachter NS, Rabinowitz D, Stohl S, Conde-Knape K, Cohn JS, Deckelbaum RJ, Berglund L, Shea S (2003) The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children. Atherosclerosis 179:387–393CrossRef Shachter NS, Rabinowitz D, Stohl S, Conde-Knape K, Cohn JS, Deckelbaum RJ, Berglund L, Shea S (2003) The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children. Atherosclerosis 179:387–393CrossRef
15.
go back to reference Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS (2002) Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res 43:2136–2145PubMedCrossRef Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS (2002) Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res 43:2136–2145PubMedCrossRef
16.
go back to reference Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484PubMed Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484PubMed
17.
go back to reference Shachter NS (2001) Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12:297–304PubMedCrossRef Shachter NS (2001) Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12:297–304PubMedCrossRef
18.
go back to reference Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, Graf JD, Dayer JM, Ricou B (2004) Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 32:632–637PubMedCrossRef Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, Graf JD, Dayer JM, Ricou B (2004) Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 32:632–637PubMedCrossRef
19.
go back to reference Vermont CL, den Brinker M, Kakeci N, de Kleijn ED, de Rijke YB, Joosten KF, de Groot R, Hazelzet JA (2005) Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 33:1610–1615PubMedCrossRef Vermont CL, den Brinker M, Kakeci N, de Kleijn ED, de Rijke YB, Joosten KF, de Groot R, Hazelzet JA (2005) Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 33:1610–1615PubMedCrossRef
20.
go back to reference Chien JY, Jerng JS, Yu CJ, Yang PC (2005) Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 33:1688–1693PubMedCrossRef Chien JY, Jerng JS, Yu CJ, Yang PC (2005) Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 33:1688–1693PubMedCrossRef
Metadata
Title
Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis
Authors
Jimmy F. P. Berbée
Caroline C. van der Hoogt
Carla J. C. de Haas
Kok P. M. van Kessel
Geesje M. Dallinga-Thie
Johannes A. Romijn
Louis M. Havekes
Henk J. van Leeuwen
Patrick C. N. Rensen
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 5/2008
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-008-1006-y

Other articles of this Issue 5/2008

Intensive Care Medicine 5/2008 Go to the issue